Shares of BioAge Labs Inc. (BIOA) touched a new 52-week high of $16.18 during intraday trading yesterday, implying a gain of over 115% in just two months.
The company's lead drug candidate is BGE-102, a potent, structurally novel, orally available, brain-penetrant small molecule NLRP3 inhibitor, being developed for the treatment of patients with cardiovascular risk factors.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.